SniZtop® has been proven in 2 clinical studies.
More than 300 patients tested SniZtop® and the results are very conclusive.
The efficacy of SniZtop® on the reduction of rhinitis symptoms acutely experienced by subjects upon exposure to a cocktail of common outdoor and indoor allergens has been proven in a randomized, double-blind, crossover, placebo-controlled study (N=43).
Subjects were exposed (by inhalation) to a standardized allergenic challenge followed by the intake of 2 tablets of SniZtop® or placebo.
Measurements were taken every 15 min, for 2 hours.
Objective measurement
of the nasal congestion
(Peak Nasal Inspiratory Flow - PNIF)
Subjective measurement
of nasal & eyes symptoms
(Visual analogue scale (VAS) score)
Adverse Event Analysis
SniZtop® provides allergy relief within 10 to 15 minutes.
All bothersome allergy symptoms were significantly reduced.
Subjects' perceived feeling of well-being was highly improved.
SniZtop® efficacy on the alleviation of eczematous lesions, itching sensation and on improvement within the quality of life in patients with Atopic Dermatitis (N=281).
Subjects were divided in 4 groups:
Doses were from 1 to 4 tablets per day, and adjusted to the severity of clinical symptoms and the age of the patient.
The whole observation period lasted 8 weeks with follow up visit every 4 weeks.
Surface of skin affected
SCORAD score
(index dedicated to the diagnosis, treatment, and management
of Atopic Dermatitis)
Itching sensation, sleep disorders,
oedema, redness, erosions
and lichenification
Sniztop® significantly improved all symptoms of atopic dermatitis with a reduction of the itching sensation in 80% of patients
within 1 month of treatment.
Quality of sleep has also been consequently improved in 79% of young children (< 5 years old).